ArticlePLoS pathogens2021
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- A multitargeting nanoparticle-based vaccine for enhanced anticancer immunotherapy in HER2-Positive breast cancer.Materials today. Bio · 2026Article
- Review
- Rational design of an optimized ferritin nanoparticle vaccine targeting both SARS-CoV-2 and MERS-CoV.Journal of nanobiotechnology · 2026Article
- Structural mimics of SARS-CoV-2.Infection · 2026Review
- A Self-Assembling β-Annulus Nanoparticle Vaccine Incorporating OX40L Confers Partial Protection Against NADC30-Like PRRSV in Piglets.Transboundary and emerging diseases · 2026Article
- Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.Journal of virology · 2025Article
- Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates.Nature communications · 2025Article
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice.International journal of nanomedicine · 2025Article
- Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.Vaccine · 2024Article
- Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate.PLoS pathogens · 2024Article
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.Cell · 2024Article
- Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants.PLoS pathogens · 2024Article
- Structure-guided in vitro evolution of nanobodies targeting new viral variants.PLoS pathogens · 2024Article
- Structural basis for mouse receptor recognition by bat SARS2-like coronaviruses.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Review
- Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.bioRxiv : the preprint server for biology · 2024Article
- COVID-19 Variants and Vaccine Development.Viruses · 2024Review
- Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.Nature communications · 2024Article
- A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies.JCI insight · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
The key to battling the COVID-19 pandemic and its potential aftermath is to develop a variety of vaccines that are efficacious and safe, elicit lasting immunity, and cover a range of SARS-CoV-2 variants. Recombinant viral receptor-binding domains (RBDs) are safe vaccine candidates but often have limited efficacy due to the lack of virus-like immunogen display pattern. Here we have developed a novel virus-like nanoparticle (VLP) vaccine that displays 120 copies of SARS-CoV-2 RBD on its surface. This VLP-RBD vaccine mimics virus-based vaccines in immunogen display, which boosts its efficacy, while maintaining the safety of protein-based subunit vaccines. Compared to the RBD vaccine, the VLP-RBD vaccine induced five times more neutralizing antibodies in mice that efficiently blocked SARS-CoV-2 from attaching to its host receptor and potently neutralized the cell entry of variant SARS-CoV-2 strains, SARS-CoV-1, and SARS-CoV-1-related bat coronavirus. These neutralizing immune responses induced by the VLP-RBD vaccine did not wane during the two-month study period. Furthermore, the VLP-RBD vaccine effectively protected mice from SARS-CoV-2 challenge, dramatically reducing the development of clinical signs and pathological changes in immunized mice. The VLP-RBD vaccine provides one potentially effective solution to controlling the spread of SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.